KEY FEATURES
| Full Name | Basic Fibroblast Growth Factor |
|---|---|
| Synonym | FGF-2;B-FGF;BFGF;FGFB;HBGF-2;prostatropin;heparin-binding growth factor 2;FGF-β; |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 31.25-2000pg/mL |
| Sensitivity | 18.75pg/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human bFGF/FGF2 in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human bFGF/FGF2. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human bFGF/FGF2 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human bFGF/FGF2, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human bFGF/FGF2. You can calculate the concentration of Human bFGF/FGF2 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Human bFGF/FGF2 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (pg/mL) | 103.85 | 249.22 | 881.48 | 112.33 | 246.76 | 833.49 |
| Standard deviation | 6.56 | 11.02 | 46.37 | 6.86 | 11.82 | 28.09 |
| CV(%) | 6.32 | 4.42 | 5.26 | 6.11 | 4.79 | 3.37 |
RECOVERY
The recovery of Human bFGF/FGF2 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 92-105 | 100 |
| EDTA plasma (n=8) | 94-109 | 101 |
| Cell culture media (n=8) | 88-98 | 93 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human bFGF/FGF2 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Pathways associated with ELISA Kit
| Activated Point Mutants Of FGFR2 Pathway | Activated Point Mutants Of FGFR2 Pathway |
| Adaptive Immune System Pathway | Adaptive Immune System Pathway |
| Angiogenesis Pathway | Angiogenesis Pathway |
| Angiopoietin Receptor Tie2-mediated Signaling Pathway | Angiopoietin Receptor Tie2-mediated Signaling Pathway |
| Cardiac Progenitor Differentiation Pathway | Cardiac Progenitor Differentiation Pathway |
| Constitutive PI3K/AKT Signaling In Cancer Pathway | Constitutive PI3K/AKT Signaling In Cancer Pathway |
| DAP12 Interactions Pathway | DAP12 Interactions Pathway |
| DAP12 Signaling Pathway | DAP12 Signaling Pathway |
| Disease Pathway | Disease Pathway |
| Downstream Signaling Events Of B Cell Receptor (BCR) Pathway | Downstream Signaling Events Of B Cell Receptor (BCR) Pathway |
Diseases associated with FGF2 ELISA Kit
| Neoplasms | publications with FGF2 and Neoplasms |
| Nervous System Diseases | publications with FGF2 and Nervous System Diseases |
| Necrosis | publications with FGF2 and Necrosis |
| Wounds and Injuries | publications with FGF2 and Wounds and Injuries |
| Heart Diseases | publications with FGF2 and Heart Diseases |
| Inflammation | publications with FGF2 and Inflammation |
| Myocardial Ischemia | publications with FGF2 and Myocardial Ischemia |
| Drug Toxicity | publications with FGF2 and Drug Toxicity |
| Disease Progression | publications with FGF2 and Disease Progression |
| Lung Diseases | publications with FGF2 and Lung Diseases |
Organs/Tissues associated with FGF2 ELISA Kit
| Vascular | publications with FGF2 and Vascular |
| Brain | publications with FGF2 and Brain |
| Muscle | publications with FGF2 and Muscle |
| Bone | publications with FGF2 and Bone |
| Embryonic Tissue | publications with FGF2 and Embryonic Tissue |
| Eye | publications with FGF2 and Eye |
| Skin | publications with FGF2 and Skin |
| Connective Tissue | publications with FGF2 and Connective Tissue |
| Heart | publications with FGF2 and Heart |
| Bone Marrow | publications with FGF2 and Bone Marrow |